NERLYNX is a once-daily oral therapy for 1 year

Recommended dosing is 240 mg once daily as 6 x 40 mg tablets taken by mouth with food1

Helpful guidance for patients

  • If they miss a dose, patients can continue with their next scheduled dose on the following day

  • Remind them to not try and make up for a missed dose by taking more than 1 dose (6 tablets) on any 1 day

  • They should keep track of any doses that they miss for any reason and share this with their healthcare team at their next appointment

  • Direct them to take loperamide (antidiarrheal medicine) with their first dose of NERLYNX and continue as directed to keep bowel movements to 1-2 per day

DOSING AND ADMINISTRATION GUIDE
Learn about dose modifications, antidiarrheal prophylaxis, and drug interactions with NERLYNX.
DOWNLOAD

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (≥ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.